6.JM is a 22-year-old man with T-cell acute lymphoblastic leukemia (ALL), who has been treated based on a pediatric-inspired protocol and has achieved complete remission with minimal residual disease negativity after induction therapy. In the interim maintenance phase of the protocol, during infusion of L-asparaginase, he develops a localized and transient erythematous rash on his chest and abdominal areas. Which one of the following is true?

A. Development of anti-asparaginase IgG without clinical hypersensitivity may lead to a reduction in clinical effect

B. The risk of infusion reaction is higher when L-asparaginase is infused with vincristine and prednisone

C. Pegylated asparaginase (pegaspargase) is the most immunogenic formulation of asparaginase

D. The rate of infusion reaction is higher with intramuscular injection compared with intravenous injection